A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 20 03 2024
revised: 08 05 2024
accepted: 09 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 23 5 2024
Statut: epublish

Résumé

Consensus Molecular Subtype (CMS) classification of colorectal cancer (CRC) tissues is complicated by RNA degradation upon formalin-fixed paraffin-embedded (FFPE) preservation. Here, we present an FFPE-curated CMS classifier. The CMSFFPE classifier was developed using genes with a high transcript integrity in FFPE-derived RNA. We evaluated the classification accuracy in two FFPE-RNA datasets with matched fresh-frozen (FF) RNA data, and an FF-derived RNA set. An FFPE-RNA application cohort of metastatic CRC patients was established, partly treated with anti-EGFR therapy. Key characteristics per CMS were assessed. Cross-referenced with matched benchmark FF CMS calls, the CMSFFPE classifier strongly improved classification accuracy in two FFPE datasets compared with the original CMSClassifier (63.6% versus 40.9% and 83.3% versus 66.7%, respectively). We recovered CMS-specific recurrence-free survival patterns (CMS4 versus CMS2: hazard ratio 1.75, 95% CI 1.24-2.46). Key molecular and clinical associations of the CMSs were confirmed. In particular, we demonstrated the predictive value of CMS2 and CMS3 for anti-EGFR therapy response (CMS2&3: odds ratio 5.48, 95% CI 1.10-27.27). The CMSFFPE classifier is an optimized FFPE-curated research tool for CMS classification of clinical CRC samples.

Identifiants

pubmed: 38782602
pii: 7/8/e202402730
doi: 10.26508/lsa.202402730
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
ErbB Receptors EC 2.7.10.1
Formaldehyde 1HG84L3525

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 de Back et al.

Auteurs

Tim R de Back (TR)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Tan Wu (T)

Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.
Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.

Pascale Jm Schafrat (PJ)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.
Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands.

Sanne Ten Hoorn (S)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Miaomiao Tan (M)

Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.

Lingli He (L)

Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.

Sander R van Hooff (SR)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Jan Koster (J)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.

Lisanne E Nijman (LE)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Geraldine R Vink (GR)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.

Inès J Beumer (IJ)

GenomeScan B.V., Leiden, Netherlands.

Clara C Elbers (CC)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Kristiaan J Lenos (KJ)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Dirkje W Sommeijer (DW)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
Flevohospital, Department of Internal Medicine, Almere, Netherlands.

Xin Wang (X)

Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China.

Louis Vermeulen (L)

Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands l.vermeulen@amsterdamumc.nl.
Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam, Netherlands.
https://ror.org/01n92vv28 Oncode Institute, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH